Who Is Buying Thermo Fisher Scientific? Hedge Fund Activity in 2026
See which hedge funds are buying, selling, or holding Thermo Fisher Scientific (TMO) based on latest 13F filings. 8 funds buying, institutional value $29.8B.
8 min czytaniaFact-checked against primary sources on · figures re-verified on regulator, issuer or SEC filings — not copied from other sites
Who Is Buying Thermo Fisher Scientific? Hedge Fund Activity in 2026
Thermo Fisher Scientific is the world's largest life sciences tools company — the "picks and shovels" play for biotech, pharma, and academic research. At around $491.66 per share, TMO is a premium-valued compounder that has delivered exceptional long-term returns through a combination of organic growth, disciplined M&A, and operational excellence. Whether scientists are developing gene therapies, testing water quality, or running clinical trials, Thermo Fisher's instruments and consumables are essential. The company serves over 400,000 customers globally and has built one of the widest competitive moats in the healthcare industry.
The latest 13F filings reveal an overwhelmingly bullish institutional picture, highlighted by three major hedge funds opening brand-new positions simultaneously.
Quick Answer
Across the funds we read directly from SEC filings, the largest Thermo Fisher position in the Q2 2026 13Fs (period ending 30 June 2026) is Viking Global Investors at $971M (1,937,415 shares). Measured against the size of each filer's book rather than in dollars, the most concentrated holder is Viking Global Investors, where Thermo Fisher is 2.8% of everything they report. Every figure here is aggregated by CUSIP from the filer's own information table with put/call rows excluded — a 13F lists options beside shares, and adding them together is what produces the inflated stakes quoted elsewhere. Filings lag roughly 45 days: this is positioning as of 30 June 2026, not today, and not investment advice.
Thermo Fisher Scientific Institutional Snapshot
| Metric | Value |
|---|---|
| Funds Buying | 8 |
| Funds Selling | 4 |
| Funds Holding | 6 |
| Active Funds Tracked | 18 |
| Share Price | ~$491.66 |
An 8-to-4 buy-sell ratio with 6 holding creates a solidly bullish institutional profile. The quality and conviction of the buyers make the signal even stronger.
Who holds Thermo Fisher, and how much it matters to them
Read from each filer's Q2 2026 information table (period ending 30 June 2026).
| Fund | Position | Shares | Share of the fund's 13F book |
|---|---|---|---|
| Viking Global Investors | $971M | 1,937,415 | 2.8% of $35.08B |
| Citadel Advisors | $288M | 574,992 | 0.2% of $171.84B |
| Millennium Management | $83M | 165,475 | 0.1% of $142.92B |
| Bridgewater Associates | $6.5M | 12,948 | 0.0% of $24.38B |
The last column is the one worth reading. A multi-strategy fund reporting a $100B+ book can hold a large dollar amount of Thermo Fisher that means almost nothing to it, while a concentrated fund holding less in dollars may have several percent of its entire book in the name. Rankings by dollar value hide exactly that difference.
Savings in one bank, investments in another? See it all in one place — and how many months it could carry you.
See your Freedom Runway — freeWho added and who cut
Comparing each filer's Q1 2026 table with its Q2 2026 one, by share count — the change is what shows conviction, not the size of the position.
| Fund | Q1 2026 shares | Q2 2026 shares | Change |
|---|---|---|---|
| Millennium Management | 70,696 | 165,475 | +134% |
| Citadel Advisors | 864,489 | 574,992 | -33% |
| Viking Global Investors | 1,668,025 | 1,937,415 | +16% |
| Bridgewater Associates | 14,487 | 12,948 | -11% |
A fund absent from this table reported no Thermo Fisher position in either quarter.
Related Articles
- Who Is Buying NVIDIA? Hedge Fund Activity in 2026
- Who Is Buying Apple? Hedge Fund Activity in 2026
- Who Is Buying Tesla? Hedge Fund Activity in 2026
FAQ
Why is the life-sciences tools sector a "picks and shovels" play?
Thermo Fisher sells instruments, consumables, and services that virtually every biotech, pharma, academic, and clinical research lab relies on. That positions the company as a beneficiary of overall research and diagnostic activity, regardless of which specific drug or therapy succeeds. Institutional funds often favor this exposure because it captures sector growth without single-asset clinical risk.
How does the biotech funding cycle affect Thermo Fisher's demand?
When biotech IPO windows are open and venture funding is plentiful, early-stage labs ramp instrument and consumable purchases, which lifts Thermo Fisher's bookings. During capital-constrained periods, smaller customers stretch capex and defer instrument upgrades. Funds watch biotech XBI performance, NIH budget appropriations, and pharma R&D spend as leading indicators for TMO's end markets.
What role does the installed base play in the TMO investment case?
Thermo Fisher's installed base of analyzers, mass spectrometers, and lab instruments generates recurring consumables and service revenue over multi-year lifecycles. This razor-and-blade dynamic creates predictable cash flows that compound as the installed base grows. Institutional models typically value this recurring stream at a premium to one-time hardware revenue.
How does M&A factor into Thermo Fisher's growth profile?
TMO has a long track record of acquiring complementary businesses — diagnostics, bioproduction, lab services — and integrating them into its commercial engine. The cadence of deals provides optionality on top of organic growth and supports cross-selling into the installed base. Funds price in management's deal-making discipline alongside the underlying market growth rate.
What macro factors most influence TMO's end-market demand?
Pharma R&D budgets, NIH and global research funding, biotech capital availability, and clinical trial activity all shape demand. Currency moves matter as well, given Thermo Fisher's global revenue footprint. Institutional buyers triangulate these inputs to gauge whether the life-sciences capex cycle is in early recovery, mid-cycle, or late-cycle territory.